Complications and Management of Dermatomyositis

Major Complications

Proximal muscle weakness, atrophy, and persistent weakness despite treatment are common muscle complications in dermatomyositis patients 1
Interstitial lung disease (ILD) is present in approximately 8% of patients and can be asymptomatic but represents a significant cause of morbidity and mortality 3
Cardiac involvement, including pericarditis, myocarditis, systolic and diastolic dysfunction, and arrhythmias, is a significant complication in dermatomyositis patients 3
Calcinosis develops on average 2.9 years after disease onset, causing pain and functional impairment in dermatomyositis patients 3

The American College of Rheumatology recommends laboratory testing, including muscle enzymes and inflammatory markers, for the diagnosis of dermatomyositis 4
Pulmonary evaluation, including pulmonary function tests, is essential for diagnosing interstitial lung disease in dermatomyositis patients 3
Imaging studies, such as high-resolution CT and MRI, are helpful in diagnosing and monitoring dermatomyositis complications 3, 4

The European League Against Rheumatism recommends steroid-sparing agents, such as methotrexate and azathioprine, to avoid prolonged corticosteroid exposure in dermatomyositis patients 4
Interstitial lung disease may require more aggressive immunosuppression with cyclophosphamide or mycophenolate in dermatomyositis patients 3

Regular disease activity assessment using validated tools, such as the Disease Activity Score, is essential for monitoring dermatomyositis patients 2
Yearly evaluation of damage using standardized measures, such as the Myositis Damage Index, is recommended for dermatomyositis patients 2
Pulmonary monitoring with regular pulmonary function tests is crucial for patients with interstitial lung disease 3
Cardiac monitoring with repeated cardiac evaluation is necessary for high-risk dermatomyositis patients 3

Delayed diagnosis and treatment can lead to increased complications and poor outcomes in dermatomyositis patients 4
Inadequate immunosuppression is associated with a greater risk of calcinosis and lipodystrophy in dermatomyositis patients 2
Overlooking cardiac involvement can be potentially life-threatening in dermatomyositis patients 3
Rapid corticosteroid tapering may lead to disease flare in dermatomyositis patients 4
Neglecting psychosocial support can impair quality of life in dermatomyositis patients 2